TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29977205
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention to enhance medication adherence
Study: 29977284
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of serum TFF3 and pepsinogen
Study: 29978216
Drug: BIND-014 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIND-014 (60 mg/m2 intravenously on day 1 of 21-day cycles in combination with prednisone)
Study: 29978298
Drug: Ultrasound-guided left
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided left lateral TAP block combined with RS block (15 ml of 0.5% ropivacaine for TAP and 10 ml of 0.5% ropivacaine for RS)
Study: 29980242
Drug: Daily second-hand
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily second-hand tobacco smoke (SHS) exposure
Study: 29980242
Drug: Daily second-hand
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily second-hand tobacco smoke (SHS) exposure among women
Study: 29980242
Drug: Daily second-hand
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily second-hand tobacco smoke (SHS) exposure among men
Study: 29980490
Drug: FOLFIRI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI + Aflibercept (4 mg/kg body weight delivered intravenously every 2 weeks for a maximum of 12 cycles, followed by aflibercept maintenance)
Study: 29980535
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg β3-AR agonist mirabegron
Study: 29980535
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg β3-AR agonist mirabegron
Study: 29980537
Drug: HDC/IL2 (histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDC/IL2 (histamine dihydrochloride and low-dose interleukin-2)
Study: 29980542
Drug: Selective CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective CT fluoroscopy transforaminal epidural steroid (arm 1)
Study: 29980542
Drug: 15 days
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 days tapering dose of oral steroids (arm 3)
Study: 29980542
Drug: Sham epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham epidural and oral placebo control (arm 4)
Study: 29980894
Drug: AMG 900
Normalized name: AMG-900
DrugBank: AMG-900 (DB17197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 900 at 40 mg/day with G-CSF
Study: 29980907
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and axillary dissection
Study: 29981205
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + 1% MtF gel
Study: 29981205
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + AV gel
Study: 29982198
Drug: Daily perception
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily perception of fetal hiccups
Study: 29982217
Drug: Oral propranolol-hydrochloride
Normalized name: Propranolol Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol-hydrochloride (1.6 mg/kg/day in three to four divided dosages) until discharge, for a maximum of 10 weeks.
Study: 29982218
Drug: Azithromycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (single oral dose at months 6, 9, 12, and 15)
Study: 29982218
Drug: Nicotinamide (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (daily oral dose given to mother for breastfeeding children aged 0-6 months and directly to children aged 6-18 months)
Study: 29982449
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusions using flucloxacillin
Study: 29982449
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusions using cefepime
Study: 29982449
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusions using vancomycin
Study: 29982449
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusions using piperacillin/tazobactam
Study: 29982449
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusions
Study: 29982514
Drug: Pivmecillinam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 200 mg three times daily for ≤5 days
Study: 29982514
Drug: Pivmecillinam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 400 mg three times daily
Study: 29983087
Drug: Veliparib (PARP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (PARP inhibitor)
Study: 30029855
Drug: Ivacaftor treatment
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ivacaftor treatment for 3 months
Study: 29983992
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation therapy (CRT) + Teach the Parent
Study: 29983992
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation therapy (CRT) + contact control (Family Fun Time)
Study: 29984044
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy as an adjunct to sterile saline
Study: 29984608
Drug: Overused drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overused drug withdrawal with optional preventive medication
Study: 29986085
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (Xyrem) oral solution, median dose 4.5 g per night at start, 6 g per night throughout study, in two equal doses.
Study: 29986672
Drug: SMS reminder
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS reminder (weekly)
Study: 29986691
Drug: Bendamustine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 75 mg/m²
Study: 29986845
Drug: WelTel short-message
Approvals — FDA: no, EMA: no, PMDA: no
Description: WelTel short-message service (SMS) mHealth program; participants received mobile phones with unlimited texting and weekly bidirectional text messages for one year
Study: 29986852
Drug: Lenalidomide at
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide at 10-, 15-, and 20-mg dose levels
Study: 29986852
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance after salvage with high-dose methotrexate or focal irradiation
Study: 29987139
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet of dolutegravir (50 mg) and rilpivirine (25 mg)
Study: 29987139
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of dolutegravir and rilpivirine (reference treatment)
Study: 29987139
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet
Study: 29987142
Drug: Ciprofloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (10 to 15 mg/kg body weight every 12 h)
Study: 29988503
Drug: Preventive Dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive Dexamethasone Treatment
Study: 29988921
Drug: Bortezomib (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (4 doses of 1.3 mg/m2 i.v.)
Study: 29989854
Drug: Ado-trastuzumab emtansine
Normalized name: Ado-Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression
Study: 29991024
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg once daily
Study: 29991428
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) for 8 weeks (n = 29)
Study: 29992019
Drug: Glycated low-density
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycated low-density lipoprotein (g-LDL)
Study: 29992039
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg a day taken orally
Study: 29992080
Drug: IgM antibody
Normalized name: IgM antibody to ganglioside
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM antibody specific to pneumococcal surface protein A (PspA)
Study: 29992080
Drug: IgM antibody
Normalized name: IgM antibody to ganglioside
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM antibody specific to an unencapsulated pneumococcal strain
Study: 29992241
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg every 2 weeks until disease progression or intolerable toxicity for up to 24 months
Study: 29992396
Drug: Cladribine Tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine Tablets (MAVENCLAD) with treatment postponement in year 2 based on ALC recovery
Study: 29992396
Drug: Cladribine Tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine Tablets (MAVENCLAD) with treatment algorithm applied
Study: 29992396
Drug: Cladribine Tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine Tablets (MAVENCLAD)
Study: 29992599
Drug: Nurses' solution-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurses' solution-focused communication
Study: 29996829
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment plans
Study: 29997136
Drug: Cyclosporine starting
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine starting dose of 5 mg/kg/day, decreasing to 3-3.5 mg/kg/day after 8 weeks
Study: 29997898
Drug: Provider intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provider intervention with patient-specific OA treatment recommendations
Study: 30001986
Drug: Lirilumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lirilumab (3 mg/kg) as a single agent for lower-risk MDS patients
Study: 30001986
Drug: Lirilumab in
Normalized name: Lirilumab
DrugBank: Lirilumab (DB11754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lirilumab in combination with azacitidine (75 mg/m2) for higher-risk MDS patients
Study: 30001986
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events attributable to study drug
Study: 30001987
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg/day plus cetuximab 400 mg/m
Study: 30001987
Drug: Pazopanib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 600 mg/day
Study: 30001990
Drug: LTLD (liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTLD (liposomal targeted drug delivery) followed by focused ultrasound exposure
Study: 30002106
Drug: Chronic breathlessness
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic breathlessness treatment
Study: 30002106
Drug: Chronic pain
Normalized name: Aspirin 81 mg ORAL TABLET [Chronic Pain/Fever Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic pain treatment
Study: 30002113
Drug: NT-proBNP measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP measurement at enrollment (threshold of 1000 pg/mL)
Study: 30002113
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HeartLogic and NT-proBNP measurements
Study: 30002864
Drug: Subcutaneous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous golimumab induction (200 mg initially and 100 mg at week 2) followed by maintenance (50 mg or 100 mg every 4 weeks until week 54)
Study: 30003118
Drug: BAX 335,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAX 335, an AAV8-based hemophilia B gene therapy vector designed to express the FIX Padua variant.
Study: 30003118
Drug: Phage display
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phage display technology to develop a Fab2 mini-antibody selectively binding to FIX Padua.
Study: 30003579
Drug: Conventional analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analysis (assumed treatment effect on mean only)
Study: 30003996
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by consolidative radiation therapy (CRT)
Study: 30005644
Drug: Low-dose Neu2000
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Neu2000 (2.75 g)
Study: 30005644
Drug: High-dose Neu2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Neu2000 (5.25 g)
Study: 30006326
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention (weekly SMS messages including medical information, compliance importance, appointment reminders)
Study: 30009214
Drug: Single sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single sequential microelectrode recordings
Study: 30009213
Drug: DaxibotulinumtoxinA (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: DaxibotulinumtoxinA (up to 200 U, single open-label intramuscular dose)
Study: 30009275
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) consisting of 10 telephone-based sessions with an accompanying workbook
Study: 30009275
Drug: Yoga consisting
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga consisting of 10 weeks of group yoga classes (twice a week) modified for older adults
Study: 30009815
Drug: Fructose (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (35 g) dissolved in 300 mL water
Study: 30009815
Drug: Lactose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (50 g) dissolved in 300 mL water
Study: 30009894
Drug: pEYS606 (non-viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: pEYS606 (non-viral gene therapy)
Study: 30010630
Drug: aHLH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: aHLH treatment
Study: 30010891
Drug: Adalimumab treatment
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab treatment for at least 6 months
Study: 30012192
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral (DAA) treatment at the local tertiary institution (standard care arm)
Study: 30012192
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral (DAA) treatment at their primary healthcare services (intervention arm)
Study: 30012528
Drug: Pembrolizumab 100
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 100 mg 3-weekly, starting 2 weeks before weekly adaptive bladder radiation therapy to a dose of 36 Gy in 6 fractions
Study: 30012528
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of weekly radiation therapy with pembrolizumab
Study: 30012756
Drug: Murepavadin (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Murepavadin (novel antipseudomonal antibiotic); single-dose administration; specific dosage not mentioned.
Study: 30012767
Drug: Levofloxacin at
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin at doses of 11, 14, 17, or 20 mg/kg/day (minimum, 750 mg)
Study: 30012788
Drug: m-RESIST solution
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-RESIST solution (three mHealth tools: an app, wearable, and a web-based platform)
Study: 30013511
Drug: E2 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 levels between 14.0 and 17.4 pg/ml
Study: 30013511
Drug: E2 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 levels ≤10.5 pg/ml
Study: 30013511
Drug: E2 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 levels 10.6-13.9 pg/ml
Study: 30013511
Drug: E2 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 levels ≥17.5 pg/ml
Study: 30013815
Drug: Phentermine-Topiramate Extended
Normalized name: phentermine / topiramate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine-Topiramate Extended Release, dosage and duration not available
Study: 30015290
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GM and PCR (BAL) with BDG (serum)
Study: 30016392
Drug: Vistusertib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vistusertib (50 mg bd for 3/7 days) in combination with weekly paclitaxel (80 mg/m2 for 6/7 weeks) in HGSOC
Study: 30016392
Drug: Vistusertib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vistusertib (25 mg bd after dose reduction) in combination with weekly paclitaxel (80 mg/m2 for 6/7 weeks) in sqNSCLC
Study: 30016415
Drug: Low pulse
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pulse pressure amplification (L-PPA)
Study: 30016415
Drug: Systolic BP
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systolic BP (SBP) <130 mm Hg (L-SBP)
Study: 30016929
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (LMWH)
Study: 30016929
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (LMWH and low-dose aspirin)
Study: 30016989
Drug: Drug-eluting microsphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting microsphere chemoembolization
Study: 30017884
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg once daily as first-line treatment
Study: 30018134
Drug: Fixed-dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose subcutaneous trastuzumab (H SC) 600 mg every 3 weeks for 18 cycles
Study: 30018558
Drug: Transcranial Direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Direct Current Stimulation (tDCS), details on dosage and duration not available.
Study: 30018558
Drug: Placebo (Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Control group), details on dosage and duration not available.
Study: 30018811
Drug: TrasGEX (12-720
Approvals — FDA: no, EMA: no, PMDA: no
Description: TrasGEX (12-720 mg, intravenously every 3 weeks)
Study: 30021547
Drug: Health worker
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health worker questionnaire administered at introduction and 6 months later
Study: 30021548
Drug: CGA scores
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGA scores during the course of therapy (CGA1-4)
Study: 30026059
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 or 750 mg daily)
Study: 30026110
Drug: Nilotinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib (200 mg/day)
Study: 30026275
Drug: Liraglutide (GLP-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (GLP-1 agonist), dosage and duration not specified
Study: 30026911
Drug: Multi-platform information
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-platform information and communication technology intervention for neonatal resuscitation training; details on dosage and duration not available.
Study: 30026911
Drug: Standard training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard training for neonatal resuscitation; details on dosage and duration not available.
Study: 30027104
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets 3.5 mg/kg/IFN-β
Study: 30027478
Drug: Azilsartan 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan 5 mg (for patients <50 kg)
Study: 30027478
Drug: Azilsartan 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan 10 mg (for patients ≥50 kg)
Study: 30028985
Drug: NIR intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR intraoperative imaging using TumorGlow (high-dose indocyanine green and delayed imaging)
Study: 30031556
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with intramuscular injection (olanzapine, droperidol, haloperidol, benzodiazepine, ketamine)
Study: 30032103
Drug: Work-focused cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work-focused cognitive-behavioural therapy and individual job support
Study: 30032814
Drug: Avitinib (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avitinib (150-300 mg) twice daily for cycles of 28 days
Study: 30032887
Drug: Levobupivacaine 0.25%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25%, 20 ml with epinephrine 5 μg/ml